32 related articles for article (PubMed ID: 19622303)
1. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study.
Wang Y; Chen Y; Yin H; Gu X; Shi Y; Dai G
Cancer Med; 2018 Apr; 7(4):997-1005. PubMed ID: 29532995
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Peng J; Tan C; Zeng X; Liu S
PLoS One; 2018; 13(6):e0199553. PubMed ID: 29953476
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Chao Y; Hsieh JS; Yeh HT; Su YC; Wu CC; Chen JS; Tai CJ; Bai LY; Yeh KH; Su WC; Li CP
Cancer Chemother Pharmacol; 2014 Apr; 73(4):799-806. PubMed ID: 24531611
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy.
Chen S; Feng X; Li Y; Yuan X; Zhou Z; Chen Y
Oncol Lett; 2012 Apr; 3(4):781-786. PubMed ID: 22740993
[TBL] [Abstract][Full Text] [Related]
5. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
6. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Zhao WY; Chen DY; Qi Q
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Luo HY; Xu RH; Wang F; Qiu MZ; Li YH; Li FH; Zhou ZW; Chen XQ
Chemotherapy; 2010; 56(2):94-100. PubMed ID: 20357440
[TBL] [Abstract][Full Text] [Related]
8. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
9. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Hu B; Yu JR; Wen ZZ; Shu YQ; Wang BC; Yin HR; Chen L; Bai YX; Liang J; Chen L; Cheng Y; Shen L; Zhou Y; Zhang HG; Li J; Wan DS; Chen S; Jia TZ; Jin ML
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):940-3. PubMed ID: 19173999
[TBL] [Abstract][Full Text] [Related]
10. [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Dong NN; Wang MY; Zhang Q; Liu ZF
Ai Zheng; 2009 Apr; 28(4):412-5. PubMed ID: 19622303
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.
Ma Y; Tang L; Wang HX; Xu YC; Ma Y; Zhang FC
J Clin Pharm Ther; 2012 Jun; 37(3):266-75. PubMed ID: 21950464
[TBL] [Abstract][Full Text] [Related]
12. A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.
Cheng X; Lu Y
Future Oncol; 2018 Apr; 14(8):771-779. PubMed ID: 29252007
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]